PHILADELPHIA, Jan. 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration ("FDA") granted an extension for the Company to modify its New Drug Application ("NDA") in response to a Complete Response Letter ("CRL") received November 25, 2009 for the Chronic Fatigue Syndrome ("CFS") therapeutic indication. The extension will remain open while Hemispherx submits an amended NDA.
No comments:
Post a Comment
Comments are most welcome! But please:
- No SPAM whatsoever, no supplements, no pharmaceuticals, no herbs or any other advertisements
- Absolutely no quack-doctors pushing their quack-BS websites (and if you are a quack, I will call you out)
- Be critical if you want to, but try to be coherent
Comments are moderated, because I am tired of Gerwyn-V99-The-Idiot and his moronic sockpuppets, and tired of the story of the two dogs, but I will try to publish everything else.
If you are not Gerwyn (and want to tell me something other than the story of the two dogs), then relax and write something! :-)